CSL News: Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart fail - 5th Jun 2023, 11:00pm

annb0t

Top 20
Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with symptomatic heart failure who have iron deficiency

ST. GALLEN, Switzerland, June 5, 2023 /PRNewswire/ -- CSL Vifor today announced that the U.S. Food and Drug Administration (FDA) has granted its partner American Regent, Inc., a Daiichi Sankyo Group company, approval for Injectafer® for the treatment of ...

>>> Read more: Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
 
Top Bottom